Nantahala Capital Management LLC Trims Stock Holdings in Assertio Holdings, Inc. (NASDAQ:ASRT)

Nantahala Capital Management LLC lowered its holdings in Assertio Holdings, Inc. (NASDAQ:ASRT) by 8.9% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 8,148,336 shares of the company’s stock after selling 800,000 shares during the period. Nantahala Capital Management LLC owned about 0.09% of Assertio worth $7,098,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of ASRT. Stifel Financial Corp bought a new position in Assertio during the 4th quarter worth approximately $27,000. Commonwealth Equity Services LLC bought a new position in Assertio during the 4th quarter worth approximately $30,000. Sonora Investment Management Group LLC bought a new position in Assertio during the 4th quarter worth approximately $39,000. Wealthfront Advisers LLC bought a new position in Assertio during the 4th quarter worth approximately $53,000. Finally, Thurston Springer Miller Herd & Titak Inc. lifted its holdings in Assertio by 33.7% during the 4th quarter. Thurston Springer Miller Herd & Titak Inc. now owns 67,500 shares of the company’s stock worth $59,000 after buying an additional 17,000 shares during the last quarter. Hedge funds and other institutional investors own 48.96% of the company’s stock.

Assertio Stock Down 1.9 %

Shares of Assertio stock opened at $0.62 on Monday. The company has a current ratio of 2.01, a quick ratio of 1.57 and a debt-to-equity ratio of 0.30. The business’s 50 day simple moving average is $0.70 and its 200-day simple moving average is $0.84. The stock has a market capitalization of $59.19 million, a price-to-earnings ratio of -0.85, a PEG ratio of 3.25 and a beta of 0.56. Assertio Holdings, Inc. has a twelve month low of $0.51 and a twelve month high of $1.80.

Analyst Ratings Changes

ASRT has been the topic of a number of research analyst reports. Industrial Alliance Securities set a $1.75 target price on Assertio in a report on Friday, March 14th. HC Wainwright reduced their target price on Assertio from $4.00 to $3.50 and set a “buy” rating on the stock in a report on Wednesday, March 19th. Finally, StockNews.com raised Assertio from a “hold” rating to a “buy” rating in a report on Monday, April 14th.

About Assertio

Assertio Holdings, Inc, a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis.